In This Issue

• In This Issue/Research Watch/News in Brief
• From the IASLC Tobacco Control Committee

Editorials

• Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors
• EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents
• Determining Whether YAP1 and POU2F3 Are Antineuroendocrine Factors

Editorial - Lung Cancer Worldwide

• Lung Cancer in Rwanda

Original Articles

• Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC
• Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
• Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
• POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC

Brief Reports

• Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide
• Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy

Letters to the Editor

• Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic NSCLC
• A Response to the Letter to the Editor: “Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic Non-Small Cell Lung Cancer”
• Is It Time for a Specific Nodal Assessment for Every NSCLC Stage?
• Comment on “Is It Time for a Specific Nodal Assessment for Every NSCLC Stage?”
• Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations
• Reply to Binghao Zhao et al
• Incorporating Genetic Biomarkers in WHO Classification of Lung Cancer
• 2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification
• Nontumor cells in Tumor Specimens Impair the Accuracy of Quantitative Polymerase Chain Reaction in the Detection of Programmed Death-Ligand 1 Copy Number Variant and mRNA Expression
• Response to “Non-Tumor Cells in Tumor Specimens Impair the Accuracy of qPCR in the Detection of PD-L1 CNV and mRNA Expression”
• Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered
• In Response to Continuation of Lorlatinib Beyond Progressive Disease

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports